Trial Profile
A multicenter, retrospective study to evaluate the biomarker bone scan index to predict outcome in real-life in patients with metastatic castration resistant prostate cancer on abiraterone acetate
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2015
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 25 Aug 2015 New trial record